Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAT Phathom Pharmaceuticals

Post-Mkt 01-15 18:40:08 EST

14.98

-0.16

-1.06%

盘后14.98

+0.000.00%

16:20 EST

High15.14	Low14.39	Vol791.25K
Open15.05	D1 Closing15.14	Amplitude4.95%
Mkt Cap1.17B	Tradable Cap862.35M	Total Shares78.29M
T/O11.75M	T/O Rate1.37%	Tradable Shares57.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PHAT","market":"US","secType":"STK","nameCN":"Phathom Pharmaceuticals","latestPrice":14.98,"timestamp":1768510800000,"preClose":15.14,"halted":0,"volume":791245,"hourTrading":{"tag":"盘后","latestPrice":14.98,"preClose":14.98,"latestTime":"16:20 EST","volume":14205,"amount":212814.892245,"timestamp":1768512000375},"delay":0,"floatShares":57566899,"shares":78294775,"eps":-3.801026,"marketStatus":"Post-Mkt","change":-0.16,"latestTime":"01-15 18:40:08 EST","open":15.05,"high":15.1399,"low":14.39,"amount":11751846.603397,"amplitude":0.049531,"askPrice":16.21,"askSize":2531,"bidPrice":14.32,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-3.801026,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768525200000},"marketStatusCode":4,"adr":0,"listingDate":1571976000000,"exchange":"NASDAQ","adjPreClose":15.14,"preHourTrading":{"tag":"盘前","latestPrice":15.06,"preClose":15.14,"latestTime":"09:29 EST","volume":541,"amount":8206.539905,"timestamp":1768487399999},"postHourTrading":{"tag":"盘后","latestPrice":14.98,"preClose":14.98,"latestTime":"16:20 EST","volume":14205,"amount":212814.892245,"timestamp":1768512000375},"volumeRatio":0.306571,"impliedVol":1.0841,"impliedVolPercentile":0.4661},"requestUrl":"/m/hq/s/PHAT/wiki","defaultTab":"wiki","newsList":[{"id":"2602539538","title":"Assessing Phathom Pharmaceuticals (PHAT) Valuation After Recent Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2602539538","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602539538?lang=en_us&edition=fundamental","pubTime":"2026-01-11 03:16","pubTimestamp":1768072618,"startTime":"0","endTime":"0","summary":"What recent performance says about Phathom Pharmaceuticals\nWithout a single clear news catalyst, Phathom Pharmaceuticals (PHAT) has still drawn attention after a recent month of modest gains, a stronger move over the past 3 months, and a sharply positive 1 year total return.\nThose returns sit against a value score of 4 and a share price of about $15.02 at the last close. This has prompted some investors to compare that recent performance with the company’s current fundamentals.\nSee our latest...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/assessing-phathom-pharmaceuticals-phat-valuation-after-recen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/assessing-phathom-pharmaceuticals-phat-valuation-after-recen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2602731392","title":"Phathom Pharmaceuticals Announces $130 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2602731392","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602731392?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:36","pubTimestamp":1767908161,"startTime":"0","endTime":"0","summary":"An update from Phathom Pharmaceuticals ( ($PHAT) ) is now available. On January 7, 2026, Phathom Pharmaceuticals entered into an underwriting agree...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/phathom-pharmaceuticals-announces-130-million-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/phathom-pharmaceuticals-announces-130-million-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2601958623","title":"Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601958623","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601958623?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:01","pubTimestamp":1767884460,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phathom Pharmaceuticals (PHAT – Research Report), InMode (INMD – ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phathom-pharmaceuticals-phat-inmode-inmd-and-bristol-myers-squibb-bmy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phathom-pharmaceuticals-phat-inmode-inmd-and-bristol-myers-squibb-bmy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","LU1718418525.SGD","LU1093756325.SGD","LU0321505439.SGD","LU0029874061.USD","LU1291159041.SGD","IE00BSNM7G36.USD","LU0128526141.USD","LABU","LU0306806265.USD","LU0225771236.USD","BK4007","LU2360032135.SGD","LU1868836914.USD","LU2125154778.USD","LU0868494617.USD","LU1670710661.SGD","LU1989771016.USD","LU1032466523.USD","BK4082","LU2125154935.USD","PHAT","LU1261432733.SGD","XLV","LU1868836757.USD","LU1868837300.USD","LU0114720955.EUR","LU0321505868.SGD","LU1670711123.USD","IE00BJJMRZ35.SGD","LU1585245621.USD","BK4532","HCSG","LU1868836591.USD","BK4588","LU0882574055.USD","IE0009355771.USD","BK4534","XBI","BMY","INMD","LU0225284248.USD","LU1323610961.USD","LU1430594728.SGD","LU1670710588.SGD","IE00B2B36J28.USD","BK4559","LU2133065610.SGD","IE00BFXG1179.USD","LU0061475181.USD"],"gpt_icon":0},{"id":"2601360407","title":"BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike","url":"https://stock-news.laohu8.com/highlight/detail?id=2601360407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601360407?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:21","pubTimestamp":1767882071,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, NikeEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL6N3Y90NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEM","SCCO","COMP","HOUS","KTOS","BK4596","DRI","NEOG","HBBD.SI","SHOO","LU0396098781.USD","RVMD","MPC","IE00B4R5TH58.HKD","89988","TFX","VNDA","LU0868494708.USD","APD","VLO","NOC","HELE","STZ","GLUE","JCAP","ABBV","NKE","PHAT","ALBmain","TYL","GM","F","HL","LU2097828805.USD","LU1267930227.SGD","MLTX","CDE","AA","LNN","BW","RTX","LU0577902298.EUR"],"gpt_icon":1},{"id":"2601013364","title":"Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2601013364","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601013364?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:06","pubTimestamp":1767877560,"startTime":"0","endTime":"0","summary":"U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Thursday.Shares of Immuneering Corp  fell sharply in pre-market trading.The company announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, with over 13 months median follow up time.Immuneering shares dipped 20.7% to $6.61 in pre-market trading.Here are some other stocks moving lower in pre-market trading.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/08/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/08/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49780387/immuneering-phathom-pharmaceuticals-canadian-solar-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49780387/immuneering-phathom-pharmaceuticals-canadian-solar-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4585","PHAT","BK4139","BK4563","IMRX","BK4007","BK4141","BK4588","BK4526","BK4539","BK4519"],"gpt_icon":1},{"id":"2601369317","title":"BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, General Motors, Ford","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369317","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369317?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:12","pubTimestamp":1767874343,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, General Motors, FordEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL6N3Y90PT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GM","LU0654597011.USD","IE00B4R5TH58.HKD","GLUE","LU0689472784.USD","LU0788109121.HKD","HBM","RTX","RVMD","SCCO","F","ABBV","BK4555","IE00B3S45H60.SGD","IE00BDGV0183.EUR","LU1992135472.HKD","IE00BZ9MQY76.HKD","LU0310800379.SGD","LU0203345920.USD","LU1934455194.USD","BK4559","BK4550","BK4588","BK4168","KTOS","LU0234570918.USD","IE00BJJMRZ35.SGD","HL","LU0256863811.USD","BK4169","NOC","PHAT","SG9999001143.SGD","LU1064131342.USD","LU2237443465.HKD","STZ","NEM","TECK","BK4596","CDE","LU0006061336.USD","AA","LU0612318971.USD","LU0211331839.USD","BK4116","LU0256863902.USD","LU1496350502.SGD"],"gpt_icon":1},{"id":"2601658143","title":"Phathom Pharmaceuticals Shares Fall 13.7% Premarket After Co Announces $130 Mln Equity Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2601658143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601658143?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:23","pubTimestamp":1767871398,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL4N3Y90RJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2601833190","title":"Phathom Pharmaceuticals Inc - Shares Sold at $16.00 Each, Pre-Funded Warrants at $15.999","url":"https://stock-news.laohu8.com/highlight/detail?id=2601833190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601833190?lang=en_us&edition=fundamental","pubTime":"2026-01-08 11:33","pubTimestamp":1767843182,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA45MS8P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2601331970","title":"Phathom Pharmaceuticals Inc - Announces Pricing of Public Offering of 6.87M Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601331970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601331970?lang=en_us&edition=fundamental","pubTime":"2026-01-08 11:33","pubTimestamp":1767843182,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA45MS8P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2601331903","title":"Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2601331903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601331903?lang=en_us&edition=fundamental","pubTime":"2026-01-08 11:33","pubTimestamp":1767843182,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA45MS8P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2601238794","title":"Stocks to Watch: Globus Medical, L3Harris, Phathom","url":"https://stock-news.laohu8.com/highlight/detail?id=2601238794","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601238794?lang=en_us&edition=fundamental","pubTime":"2026-01-08 07:58","pubTimestamp":1767830280,"startTime":"0","endTime":"0","summary":"Shares of Globus Medical rose after the company issued preliminary fourth-quarter sales numbers and a 2026 outlook that each beat analysts' expectations. The stock was up 9.5% to $99.10 in after-hours trading.L3Harris jumped in after-market trading along with other defense contractors after President Trump posted on Truth Social that the country's 2027 military budget should be $1.5 trillion dollars. The stock was recently up 5.3% to $326.12.Shares of Phathom Pharmaceuticals fell after the company said it would sell stock or warrants to buy stock through a public offering. The stock slid 12% to $15.88 in late trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN8TJ469.HKD","BK4007","LU1804176565.USD","LU0162691827.USD","LU0006061336.USD","LU2065732104.USD","BK4187","LU2265009873.SGD","LU1506573853.SGD","GMED","LU0072461881.USD","LU0314106906.USD","LHX","IE00BBT3K403.USD","IE00BLSP4452.SGD","PHAT","BK4588","IE00BLSP4239.USD","BK4082","IE00BFXG1179.USD","IE0009354923.USD"],"gpt_icon":0},{"id":"2601438781","title":"Phathom Shares Fall on Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2601438781","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601438781?lang=en_us&edition=fundamental","pubTime":"2026-01-08 07:35","pubTimestamp":1767828900,"startTime":"0","endTime":"0","summary":"Shares of Phathom Pharmaceuticals fell after the company said it would sell stock or warrants to buy stock through a public offering.The stock slid 12% to $15.88 in after-hours trading. It has more than doubled over the past 12 months.The company did not specify the size of the offering or when it would be completed. It said it would use net proceeds for working capital and commercialization and research and development expenses.On Wednesday, the company also released preliminary fourth-quarter results, expecting to report net revenues of $57 million to $58 million. Analysts polled by FactSet project fourth-quarter revenue of $56.2 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2601384876","title":"BRIEF-Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2601384876","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601384876?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:10","pubTimestamp":1767823811,"startTime":"0","endTime":"0","summary":"BRIEF-Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJan 8 (Reuters) - Phathom Pharmaceuticals Inc PHAT.O:PHATHOM PHARMACEUTICALS ANNOUNCES PROPOSED ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA58DSKC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2601814143","title":"BUZZ-Phathom Pharmaceuticals drops after announcing planned equity raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2601814143","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601814143?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:55","pubTimestamp":1767822905,"startTime":"0","endTime":"0","summary":"BUZZ-Phathom Pharmaceuticals drops after announcing planned equity raise** Phathom Pharmaceuticals PHAT.O shares down 10.1% post-market at $16.25 after planned equity raise news** Gastrointestinal  diseases-focused biopharma announces offering comprised of stock and pre-funded warrants; deal size not disclosed** Co intends to use net offering proceeds for general corporate purposes, including for working capital and commercialization and R&D expenses** Guggenheim and Cantor Fitzgerald joint bookrunners** Co also says expects Q4 net revenues of approx $57-$58 mln and cash of about $130 mln as of Dec 31** With ~71.1 mln shares outstanding, it has ~$1.3 bln market cap** PHAT shares on Weds ended up 10.4% at $18.08, up 9% to start 2026. Stock roughly doubled in 2025** 9 of 10 analysts covering rate the stock \"strong buy\" or \"buy\",  1 \"hold\"; median PT $23, per LSEG data","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL6N3Y817W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2601784389","title":"BRIEF-Phathom Pharmaceuticals Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601784389","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601784389?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:29","pubTimestamp":1767821355,"startTime":"0","endTime":"0","summary":"BRIEF-Phathom Pharmaceuticals Files For Mixed Shelf Offering Size Not Disclosed- SEC FilingJan 7  - Phathom Pharmaceuticals Inc PHAT.O:PHATHOM PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILINGSource text: [ID:n0001193125-26-006262]Further company coverage: PHAT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y81K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2601389188","title":"Phathom Pharmaceuticals Reports Q4 Preliminary Revenue of $$57 Million to $58 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389188","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389188?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:16","pubTimestamp":1767820618,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals  reported preliminary Q4 revenue late Wednesday of $57 million to $58 million.Analysts polled by FactSet expect $56.2 million.The company said it expects to achieve operating profitability in H2.The company's shares fell 12% in after-hours trading. Phathom also announced a proposed public stock offering.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHAT"],"gpt_icon":0},{"id":"2601386001","title":"Phathom Pharmaceuticals Expects Operating Profitability in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601386001","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601386001?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:01","pubTimestamp":1767819681,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals Inc. has announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, the company expects net revenues of approximately $57 million to $58 million, with GAAP operating expenses between $59 million and $61 million and non-GAAP operating expenses of $51 million to $53 million, excluding about $8 million in stock-based compensation. Net cash usage for the quarter is estimated at around $6 million, with cash and cash equivalents totaling approximately $130 million at year-end. For the full year 2025, Phathom anticipates net revenues of $174.5 million to $175.5 million. GAAP operating expenses are expected to range from $315.5 million to $317.5 million, while non-GAAP operating expenses are projected at $284.5 million to $286.5 million, excluding approximately $31 million of stock-based compensation. The company has also reported surpassing one million VOQUEZNA prescriptions dispensed in the U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL4lgCtP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014013.SGD","BK4007","IE00BGHQF748.EUR","SG9999014039.USD","LU2095319765.USD","SG9999014021.USD","LU0314104364.USD","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","BK4588","PHAT","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2601858389","title":"Phathom Pharmaceuticals Inc -  Expects Q4 Net Revenues of $57-$58 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2601858389","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601858389?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:01","pubTimestamp":1767819660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUABP9ZWS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2601079386","title":"Press Release: Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2601079386","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601079386?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:01","pubTimestamp":1767819660,"startTime":"0","endTime":"0","summary":"FLORHAM PARK, N.J., Jan. 07, 2026  -- Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal  diseases, today announced certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.-- For the three months ended December 31, 2025, Phathom expects to report:. -- Net revenues of approximately $57 million to $58 million. -- GAAP operating expenses of approximately $59 million to $61. -- Non-GAAP operating expenses of approximately $51 million to $53. million, which excludes approximately $8 million of stock-based. -- Cash and cash equivalents of approximately $130 million as of. This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States  and also certain non-GAAP financial measures. In particular, we have provided non-GAAP operating expenses, adjusted to exclude stock-based compensat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","PHAT","BK4007","R","BK4022"],"gpt_icon":0},{"id":"2590509174","title":"Raymond James Initiates Phathom Pharmaceuticals at Strong Buy With $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2590509174","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590509174?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:07","pubTimestamp":1765544869,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) has an average rating of buy and mean price target of $22.90, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RJF","PHAT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phathompharma.com","stockEarnings":[{"period":"1week","weight":-0.1626},{"period":"1month","weight":0.0306},{"period":"3month","weight":0.1375},{"period":"6month","weight":0.9044},{"period":"1year","weight":1.2297},{"period":"ytd","weight":-0.0874}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.06685},{"month":2,"riseRate":0.666667,"avgChangeRate":0.0903},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.119883},{"month":4,"riseRate":0.5,"avgChangeRate":0.053339},{"month":5,"riseRate":0.5,"avgChangeRate":-0.02431},{"month":6,"riseRate":0.666667,"avgChangeRate":0.246775},{"month":7,"riseRate":0.666667,"avgChangeRate":0.025067},{"month":8,"riseRate":0.666667,"avgChangeRate":0.15186},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.003613},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.040055},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.100392},{"month":12,"riseRate":0.714286,"avgChangeRate":0.070942}],"exchange":"NASDAQ","name":"Phathom Pharmaceuticals","nameEN":"Phathom Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phathom Pharmaceuticals,PHAT,Phathom Pharmaceuticals股票,Phathom Pharmaceuticals股票老虎,Phathom Pharmaceuticals股票老虎国际,Phathom Pharmaceuticals行情,Phathom Pharmaceuticals股票行情,Phathom Pharmaceuticals股价,Phathom Pharmaceuticals股市,Phathom Pharmaceuticals股票价格,Phathom Pharmaceuticals股票交易,Phathom Pharmaceuticals股票购买,Phathom Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction